Everolimus regulatory update

Novartis disclosed in its 4Q11 earnings that Japan approved everolimus as Certican to prevent organ rejection in adult kidney transplant patients and as Afinitor to treat pancreatic neuroendocrine tumors. Certican is already approved in Japan to prevent organ rejection in heart transplant patients. Afinitor is approved in Japan to treat non-resectable, metastatic renal cell carcinoma (RCC). ...